Price (delayed)
$1.51
Market cap
$3.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.81
Enterprise value
$3.07M
mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage
There are no recent dividends present for TNFA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.